Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452528 · ClinicalTrials.gov registry record · Phase 2
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02452528 is a Phase 2 study that was terminated before completion, run by Arrowhead Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT02452528, a Phase 2 study, was terminated before completion, sponsored by Arrowhead Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
Interventions
- DRUG Placebo
- DRUG Tenofovir
- DRUG Entecavir
- DRUG diphenhydramine
- DRUG ARC-520
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452528
The ClinicalTrials.gov registry entry for NCT02452528 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02452528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452528 about?
NCT02452528 is a clinical study titled "Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus". Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
What is the current status of trial NCT02452528?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02452528?
The interventions under investigation include: Placebo (DRUG), Tenofovir (DRUG), Entecavir (DRUG), diphenhydramine (DRUG), ARC-520 (DRUG).
Who is sponsoring clinical trial NCT02452528?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.